CURRENT ISSUE
Volume 61, Issue 1, March 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD) is nowadays considered an important risk factor not only for end-stage liver disease but also for cardiovascular diseases. The worldwide prevalence of MALSD in adult population is 38%¹. This high prevalence correlates with the increasing prevalence of obesity. Most patients with MASLD…
